Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the P/S ratio high or low?
The P/S ratio of 5.39 is 23% above its estimated 5-year average of 4.37, near the high end of its estimated 5-year range (2.90–5.82).
As of 2026-09-10T17:15:21.000Z. 25.66% above its estimated 12-month average of 4.29.
Quote observation: 2026-09-10T17:15:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 461891cb7c254590516e49e38a0a038ebc025655c5473beed5b8d845ab71f3ca
Current P/S: FMP quote market capitalization / TTM revenue. Historical estimates use price and reported weighted-average shares; daily points use adjusted close × quarterly weighted-average shares / TTM revenue. Historical series through 2026-09-09.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
5.39
PS RATIO AVG TTM
4.29
PS RATIO AVG 3Y
4.32
PS RATIO AVG 5Y
4.37
PS RATIO AVG 10Y
4.33
PS RATIO AVG 15Y
3.99
PS RATIO AVG 20Y
3.76
CURRENT VS TTM AVG
+25.66%
CURRENT VS 3Y AVG
+24.72%
CURRENT VS 5Y AVG
+23.37%
CURRENT VS 10Y AVG
+24.36%
CURRENT VS 15Y AVG
+35.12%
CURRENT VS 20Y AVG
+43.32%
SECTOR MEDIAN · HEALTHCARE
3.21
median of 86 covered companies
CURRENT VS SECTOR MEDIAN
+67.65%
vs the sector median at left
Market Cap
$355.66B
PS Ratio
0.79
TTM Avg
0.72
3Y Avg
1.03
5Y Avg
1.23
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Merck & Co., Inc. (MRK) | $357.70B | 5.39 | 4.29 | 4.32 | 4.37 |
| UnitedHealth Group Incorporated (UNH)vs › | $355.66B | 0.79 | 0.72 | 1.03 | 1.23 |
| Roche Holding AG (RHHBY)vs › | $338.24B | N/A | N/A | N/A | N/A |
| AbbVie Inc. (ABBV)vs › | $446.38B | 6.93 | 6.63 | 5.98 | 5.39 |
| AstraZeneca PLC (AZN)vs › | $247.90B | 4.04 | 4.76 | 4.56 | 4.67 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $224.54B | 4.85 | 4.53 | 4.65 | 4.92 |
| Amgen Inc. (AMGN)vs › | $206.89B | 5.43 | 5.14 | 5.19 | 5.12 |
| Novo Nordisk A/S (NVO)vs › | $197.27B | 3.86 | 4.42 | 9.74 | 10.58 |
| Gilead Sciences, Inc. (GILD)vs › | $180.04B | 5.91 | 5.59 | 4.48 | 4.02 |
| Abbott Laboratories (ABT)vs › | $179.98B | 3.86 | 4.38 | 4.75 | 4.70 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $17,183,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-05 |
| Q4 FY2025Period ended 2025-12-31 | $16,324,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-24 |
| Q1 FY2026Period ended 2026-03-31 | $16,286,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-04 |
| Q2 FY2026Period ended 2026-06-30 | $16,607,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-07 |
| TTM revenue | $66,400,000,000 |
Current P/S: $357,704,030,600 market capitalization ÷ $66,400,000,000 TTM revenue = 5.39x.
Market capitalization source: FMP quote. Quote observed 2026-09-10T17:15:21.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
At 5.39, P/S is above its estimated 20-year median — higher than 99% of readings in its estimated 20-year history.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
estimated 20-year low
1.79
median
3.91
estimated 20-year high
5.82
P/S Ratio
5.39
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PS RATIO |
|---|---|
| 2026-09-09 | 5.49 |
| 2026-09-08 | 5.53 |
| 2026-09-04 | 5.60 |
| 2026-09-03 | 5.67 |
| 2026-09-02 | 5.65 |
| 2026-09-01 | 5.58 |
| 2026-08-31 | 5.50 |
| 2026-08-28 | 5.52 |
| 2026-08-27 | 5.57 |
| 2026-08-26 | 5.70 |
| 2026-08-25 | 5.82 |
| 2026-08-24 | 5.61 |
| 2026-08-21 | 5.68 |
| 2026-08-20 | 5.55 |
| 2026-08-19 | 5.67 |
| 2026-08-18 | 5.03 |
| 2026-08-17 | 5.06 |
| 2026-08-14 | 5.06 |
| 2026-08-13 | 5.05 |
| 2026-08-12 | 4.95 |
| 2026-08-11 | 4.86 |
| 2026-08-10 | 4.87 |
| 2026-08-07 | 4.85 |
| 2026-08-06 | 4.84 |
| 2026-08-05 | 4.84 |
| 2026-08-04 | 4.82 |
| 2026-08-03 | 4.82 |
| 2026-07-31 | 4.91 |
| 2026-07-30 | 4.89 |
| 2026-07-29 | 4.91 |
| 2026-07-28 | 4.97 |
| 2026-07-27 | 4.93 |
| 2026-07-24 | 4.94 |
| 2026-07-23 | 4.92 |
| 2026-07-22 | 4.80 |
| 2026-07-21 | 4.76 |
| 2026-07-20 | 4.69 |
| 2026-07-17 | 4.81 |
| 2026-07-16 | 4.81 |
| 2026-07-15 | 4.66 |
| 2026-07-14 | 4.55 |
| 2026-07-13 | 4.67 |
| 2026-07-10 | 4.66 |
| 2026-07-09 | 4.71 |
| 2026-07-08 | 4.75 |
| 2026-07-07 | 4.86 |
| 2026-07-06 | 4.78 |
| 2026-07-02 | 4.88 |
| 2026-07-01 | 4.72 |
| 2026-06-30 | 4.84 |
| 2026-06-29 | 4.88 |
| 2026-06-26 | 4.85 |
| 2026-06-25 | 4.73 |
| 2026-06-24 | 4.55 |
| 2026-06-23 | 4.51 |
| 2026-06-22 | 4.35 |
| 2026-06-18 | 4.29 |
| 2026-06-17 | 4.35 |
| 2026-06-16 | 4.34 |
| 2026-06-15 | 4.33 |
| 2026-06-12 | 4.49 |
| 2026-06-11 | 4.55 |
| 2026-06-10 | 4.49 |
| 2026-06-09 | 4.51 |
| 2026-06-08 | 4.50 |
| 2026-06-05 | 4.55 |
| 2026-06-04 | 4.53 |
| 2026-06-03 | 4.32 |
| 2026-06-02 | 4.36 |
| 2026-06-01 | 4.34 |
| 2026-05-29 | 4.47 |
| 2026-05-28 | 4.52 |
| 2026-05-27 | 4.53 |
| 2026-05-26 | 4.51 |
| 2026-05-22 | 4.61 |
| 2026-05-21 | 4.37 |
| 2026-05-20 | 4.26 |
| 2026-05-19 | 4.31 |
| 2026-05-18 | 4.24 |
| 2026-05-15 | 4.20 |
| 2026-05-14 | 4.27 |
| 2026-05-13 | 4.28 |
| 2026-05-12 | 4.23 |
| 2026-05-11 | 4.19 |
| 2026-05-08 | 4.20 |
| 2026-05-07 | 4.23 |
| 2026-05-06 | 4.28 |
| 2026-05-05 | 4.26 |
| 2026-05-04 | 4.33 |
| 2026-05-01 | 4.30 |
| 2026-04-30 | 4.18 |
| 2026-04-29 | 4.25 |
| 2026-04-28 | 4.22 |
| 2026-04-27 | 4.22 |
| 2026-04-24 | 4.29 |
| 2026-04-23 | 4.39 |
| 2026-04-22 | 4.33 |
| 2026-04-21 | 4.31 |
| 2026-04-20 | 4.49 |
| 2026-04-17 | 4.56 |
| 2026-04-16 | 4.42 |
| 2026-04-15 | 4.52 |
| 2026-04-14 | 4.60 |
| 2026-04-13 | 4.60 |
| 2026-04-10 | 4.65 |
| 2026-04-09 | 4.70 |
| 2026-04-08 | 4.72 |
| 2026-04-07 | 4.57 |
| 2026-04-06 | 4.63 |
| 2026-04-02 | 4.63 |
| 2026-04-01 | 4.63 |
| 2026-03-31 | 4.61 |
| 2026-03-30 | 4.53 |
| 2026-03-27 | 4.58 |
| 2026-03-26 | 4.56 |
| 2026-03-25 | 4.57 |
| 2026-03-24 | 4.46 |
| 2026-03-23 | 4.43 |
| 2026-03-20 | 4.38 |
| 2026-03-19 | 4.38 |
| 2026-03-18 | 4.39 |
| 2026-03-17 | 4.44 |
| 2026-03-16 | 4.42 |
| 2026-03-13 | 4.43 |
| 2026-03-12 | 4.44 |
| 2026-03-11 | 4.45 |
| 2026-03-10 | 4.49 |
| 2026-03-09 | 4.49 |
| 2026-03-06 | 4.44 |
| 2026-03-05 | 4.45 |
| 2026-03-04 | 4.61 |
| 2026-03-03 | 4.59 |
| 2026-03-02 | 4.65 |
| 2026-02-27 | 4.74 |
| 2026-02-26 | 4.57 |
| 2026-02-25 | 4.69 |
| 2026-02-24 | 4.82 |
| 2026-02-23 | 4.82 |
| 2026-02-20 | 4.76 |
| 2026-02-19 | 4.74 |
| 2026-02-18 | 4.73 |
| 2026-02-17 | 4.73 |
| 2026-02-13 | 4.72 |
| 2026-02-12 | 4.64 |
| 2026-02-11 | 4.64 |
| 2026-02-10 | 4.56 |
| 2026-02-09 | 4.58 |
| 2026-02-06 | 4.74 |
| 2026-02-05 | 4.66 |
| 2026-02-04 | 4.60 |
| 2026-02-03 | 4.51 |
| 2026-02-02 | 4.41 |
| 2026-01-30 | 4.29 |
| 2026-01-29 | 4.21 |
| 2026-01-28 | 4.16 |
| 2026-01-27 | 4.20 |
| 2026-01-26 | 4.18 |
| 2026-01-23 | 4.21 |
| 2026-01-22 | 4.25 |
| 2026-01-21 | 4.32 |
| 2026-01-20 | 4.26 |
| 2026-01-16 | 4.23 |
| 2026-01-15 | 4.32 |
| 2026-01-14 | 4.32 |
| 2026-01-13 | 4.21 |
| 2026-01-12 | 4.25 |
| 2026-01-09 | 4.30 |
| 2026-01-08 | 4.32 |
| 2026-01-07 | 4.22 |
| 2026-01-06 | 4.23 |
| 2026-01-05 | 4.18 |
| 2026-01-02 | 4.14 |
| 2025-12-31 | 4.09 |
| 2025-12-30 | 4.13 |
| 2025-12-29 | 4.15 |
| 2025-12-26 | 4.15 |
| 2025-12-24 | 4.14 |
| 2025-12-23 | 4.09 |
| 2025-12-22 | 4.07 |
| 2025-12-19 | 3.93 |
| 2025-12-18 | 3.92 |
| 2025-12-17 | 3.86 |
| 2025-12-16 | 3.82 |
| 2025-12-15 | 3.90 |
| 2025-12-12 | 3.90 |
| 2025-12-11 | 3.85 |
| 2025-12-10 | 3.80 |
| 2025-12-09 | 3.77 |
| 2025-12-08 | 3.85 |
| 2025-12-05 | 3.88 |
| 2025-12-04 | 3.92 |
| 2025-12-03 | 3.98 |
| 2025-12-02 | 3.93 |
| 2025-12-01 | 3.96 |
| 2025-11-28 | 4.08 |
| 2025-11-26 | 4.07 |
| 2025-11-25 | 4.11 |
| 2025-11-24 | 3.90 |
| 2025-11-21 | 3.80 |
| 2025-11-20 | 3.69 |
| 2025-11-19 | 3.70 |
| 2025-11-18 | 3.75 |
| 2025-11-17 | 3.61 |
| 2025-11-14 | 3.61 |
| 2025-11-13 | 3.61 |
| 2025-11-12 | 3.56 |
| 2025-11-11 | 3.54 |
| 2025-11-10 | 3.37 |
| 2025-11-07 | 3.36 |
| 2025-11-06 | 3.34 |
| 2025-11-05 | 3.33 |
| 2025-11-04 | 3.31 |
| 2025-11-03 | 3.25 |
| 2025-10-31 | 3.39 |
| 2025-10-30 | 3.40 |
| 2025-10-29 | 3.42 |
| 2025-10-28 | 3.43 |
| 2025-10-27 | 3.47 |
| 2025-10-24 | 3.45 |
| 2025-10-23 | 3.44 |
| 2025-10-22 | 3.46 |
| 2025-10-21 | 3.46 |
| 2025-10-20 | 3.41 |
| 2025-10-17 | 3.35 |
| 2025-10-16 | 3.31 |
| 2025-10-15 | 3.32 |
| 2025-10-14 | 3.34 |
| 2025-10-13 | 3.38 |
| 2025-10-10 | 3.39 |
| 2025-10-09 | 3.45 |
| 2025-10-08 | 3.41 |
| 2025-10-07 | 3.46 |
| 2025-10-06 | 3.50 |
| 2025-10-03 | 3.52 |
| 2025-10-02 | 3.53 |
| 2025-10-01 | 3.56 |
| 2025-09-30 | 3.31 |
| 2025-09-29 | 3.10 |
| 2025-09-26 | 3.10 |
| 2025-09-25 | 3.06 |
| 2025-09-24 | 3.14 |
| 2025-09-23 | 3.15 |
| 2025-09-22 | 3.17 |
| 2025-09-19 | 3.22 |
| 2025-09-18 | 3.22 |
| 2025-09-17 | 3.20 |
| 2025-09-16 | 3.20 |
| 2025-09-15 | 3.20 |
| 2025-09-12 | 3.27 |
| 2025-09-11 | 3.36 |
| 2025-09-10 | 3.32 |
| 2025-09-09 | 3.34 |
| 2025-09-08 | 3.32 |
| 2025-09-05 | 3.34 |
| 2025-09-04 | 3.32 |
| 2025-09-03 | 3.32 |
| 2025-09-02 | 3.37 |
| 2025-08-29 | 3.32 |
| 2025-08-28 | 3.28 |
| 2025-08-27 | 3.32 |
Showing the most recent 260 of 5,030 data points. The chart above shows the full history.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
